Guggenheim Upgrades Parabilis Medicines (NASDAQ:PBLS) to Strong-Buy

Parabilis Medicines (NASDAQ:PBLS) was upgraded by research analysts at Guggenheim to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.

Other research analysts also recently issued research reports about the stock. Wall Street Zen upgraded shares of Parabilis Medicines to a “hold” rating in a report on Saturday, June 20th. Leerink Partners started coverage on shares of Parabilis Medicines in a research note on Monday. They set an “outperform” rating and a $40.00 price target on the stock. Bank of America started coverage on shares of Parabilis Medicines in a research report on Monday. They issued a “buy” rating and a $45.00 price target for the company. Finally, Evercore initiated coverage on Parabilis Medicines in a research note on Monday. They issued an “outperform” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and three have issued a Buy rating to the stock. According to MarketBeat, Parabilis Medicines currently has a consensus rating of “Buy” and a consensus price target of $41.67.

Parabilis Medicines Stock Up 1.0%

NASDAQ PBLS traded up $0.29 during trading on Monday, hitting $29.49. The company’s stock had a trading volume of 109,248 shares, compared to its average volume of 939,208. Parabilis Medicines has a 52 week low of $24.51 and a 52 week high of $34.47.

Insider Buying and Selling

In other Parabilis Medicines news, Director Alan Sebulsky purchased 12,500 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was purchased at an average cost of $20.00 per share, with a total value of $250,000.00. Following the acquisition, the director directly owned 12,500 shares of the company’s stock, valued at approximately $250,000. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Guy Levy acquired 500,000 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was acquired at an average price of $20.00 per share, with a total value of $10,000,000.00. Following the transaction, the insider owned 1,027,000 shares in the company, valued at approximately $20,540,000. The trade was a 94.88% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 530,000 shares of company stock valued at $10,723,528 in the last quarter.